<p>InflaRx（纳斯达克代码：IFRX - 获取免费报告）于周三发布了季度财报。该公司报告本季度每股收益为（$0.09），超出分析师一致预期的（$0.17）$0.08，FiscalAI 报道。</p>
<h2>InflaRx 股价上涨 26.9%</h2>
<p>周三，纳斯达克代码：IFRX 的股票上涨了 $0.53，达到 $2.50。该公司的交易量为 18,208,689 股，而其平均交易量为 1,612,826 股。InflaRx 的 12 个月最低价为 $0.71，最高价为 $2.86。该公司的 50 日简单移动平均为 $1.16，200 日简单移动平均为 $1.12。该股票的市值为 1.8073 亿美元，市盈率为 -3.29，贝塔值为 2.42。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近对该公司的持仓进行了调整。Cubist Systematic Strategies LLC 在第一季度将其在 InflaRx 的持股增加了 33.9%。Cubist Systematic Strategies LLC 目前拥有 30,053 股该公司的股票，价值 $31,000，此前在上个季度增持了 7,616 股。HRT Financial LP 在第四季度购买了 InflaRx 的新头寸，价值约 $47,000。Insigneo Advisory Services LLC 在第四季度购买了 InflaRx 的新头寸，价值约 $61,000。Quadrature Capital Ltd 在第四季度购买了 InflaRx 的新头寸，价值约 $104,000。最后，XTX Topco Ltd 在第四季度购买了 InflaRx 的新股份，价值约 $135,000。机构投资者持有该公司 42.39% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>一些研究分析师最近对该公司发表了看法。Oppenheimer 在 4 月 24 日的研究报告中开始覆盖 InflaRx。他们给予该公司 “跑赢大盘” 的评级，并设定了 $5.00 的目标价。Guggenheim 在 4 月 21 日的研究报告中重申了对 InflaRx 的 “买入” 评级，并设定了 $14.00 的目标价。最后，Weiss Ratings 在 3 月 27 日的研究报告中重申了对 InflaRx 的 “卖出（d-）” 评级。四位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 $5.80。</p>
<p><strong>获取我们关于 IFRX 的最新股票报告</strong></p>
<h2>InflaRx 公司简介</h2>
<p>（获取免费报告）</p>
<p>InflaRx N.V. 是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对补体系统的新疗法，重点关注补体-1a（C5a）通路。该公司的主要产品候选药物 vilobelimab（IFX-1）是一种单克隆抗体，旨在选择性抑制 C5a，这是一种与多种自身免疫和炎症疾病相关的强效促炎肽。InflaRx 旨在通过推进对如脓疱性汗腺炎、坏死性皮肤病和其他罕见且严重的炎症性疾病的治疗，来满足高度未满足的医疗需求。</p>
<p>Vilobelimab 已在多个 II 期临床试验中进行评估，证明其在降低关键炎症标志物和改善临床结果方面的概念验证。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 InflaRx</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 InflaRx 吗？</h2>
<p>在你考虑 InflaRx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 InflaRx 并不在名单上。</p>
<p>虽然 InflaRx 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IFRX

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

标普生物技术 ETF - SPDR

<p>InflaRx（纳斯达克代码：IFRX）报告季度每股收益为（$0.09），超出预期的（$0.17）$0.08。在公告发布后，股价上涨 26.9%，达到$2.50。机构投资者持有该股票的 42.39%，并且最近有几笔收购。分析师的评级不一，平均目标价为$5.80。InflaRx 专注于开发针对补体系统的疗法，特别是用于自身免疫和炎症性疾病</p>

<p>InflaRx (NASDAQ:IFRX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08, FiscalAI reports.</p>
<div class="lb-trans"><p>InflaRx（纳斯达克代码：IFRX - 获取免费报告）于周三发布了季度财报。该公司报告本季度每股收益为（$0.09），超出分析师一致预期的（$0.17）$0.08，FiscalAI 报道。</p>
</div><h2>InflaRx Trading Up 26.9%</h2>
<div class="lb-trans"><h2>InflaRx 股价上涨 26.9%</h2>
</div><p>Shares of NASDAQ:IFRX traded up $0.53 during trading on Wednesday, reaching $2.50. The company's stock had a trading volume of 18,208,689 shares, compared to its average volume of 1,612,826. InflaRx has a 12 month low of $0.71 and a 12 month high of $2.86. The firm's 50 day simple moving average is $1.16 and its two-hundred day simple moving average is $1.12. The stock has a market capitalization of $180.73 million, a PE ratio of -3.29 and a beta of 2.42.</p>
<div class="lb-trans"><p>周三，纳斯达克代码：IFRX 的股票上涨了 $0.53，达到 $2.50。该公司的交易量为 18,208,689 股，而其平均交易量为 1,612,826 股。InflaRx 的 12 个月最低价为 $0.71，最高价为 $2.86。该公司的 50 日简单移动平均为 $1.16，200 日简单移动平均为 $1.12。该股票的市值为 1.8073 亿美元，市盈率为 -3.29，贝塔值为 2.42。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC lifted its holdings in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock valued at $31,000 after acquiring an additional 7,616 shares during the last quarter. HRT Financial LP bought a new position in shares of InflaRx in the 4th quarter valued at about $47,000. Insigneo Advisory Services LLC bought a new position in shares of InflaRx in the 4th quarter valued at about $61,000. Quadrature Capital Ltd bought a new position in shares of InflaRx in the 4th quarter valued at about $104,000. Finally, XTX Topco Ltd bought a new stake in InflaRx in the fourth quarter worth about $135,000. Institutional investors own 42.39% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。Cubist Systematic Strategies LLC 在第一季度将其在 InflaRx 的持股增加了 33.9%。Cubist Systematic Strategies LLC 目前拥有 30,053 股该公司的股票，价值 $31,000，此前在上个季度增持了 7,616 股。HRT Financial LP 在第四季度购买了 InflaRx 的新头寸，价值约 $47,000。Insigneo Advisory Services LLC 在第四季度购买了 InflaRx 的新头寸，价值约 $61,000。Quadrature Capital Ltd 在第四季度购买了 InflaRx 的新头寸，价值约 $104,000。最后，XTX Topco Ltd 在第四季度购买了 InflaRx 的新股份，价值约 $135,000。机构投资者持有该公司 42.39% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of research analysts have recently weighed in on the company. Oppenheimer assumed coverage on InflaRx in a research report on Friday, April 24th. They set an &#34;outperform&#34; rating and a $5.00 price objective for the company. Guggenheim restated a &#34;buy&#34; rating and set a $14.00 price objective on shares of InflaRx in a research report on Tuesday, April 21st. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of InflaRx in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $5.80.</p>
<div class="lb-trans"><p>一些研究分析师最近对该公司发表了看法。Oppenheimer 在 4 月 24 日的研究报告中开始覆盖 InflaRx。他们给予该公司 “跑赢大盘” 的评级，并设定了 $5.00 的目标价。Guggenheim 在 4 月 21 日的研究报告中重申了对 InflaRx 的 “买入” 评级，并设定了 $14.00 的目标价。最后，Weiss Ratings 在 3 月 27 日的研究报告中重申了对 InflaRx 的 “卖出（d-）” 评级。四位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 $5.80。</p>
</div><p><strong>Get Our Latest Stock Report on IFRX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 IFRX 的最新股票报告</strong></p>
</div><h2>InflaRx Company Profile</h2>
<div class="lb-trans"><h2>InflaRx 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.</p>
<div class="lb-trans"><p>InflaRx N.V. 是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对补体系统的新疗法，重点关注补体-1a（C5a）通路。该公司的主要产品候选药物 vilobelimab（IFX-1）是一种单克隆抗体，旨在选择性抑制 C5a，这是一种与多种自身免疫和炎症疾病相关的强效促炎肽。InflaRx 旨在通过推进对如脓疱性汗腺炎、坏死性皮肤病和其他罕见且严重的炎症性疾病的治疗，来满足高度未满足的医疗需求。</p>
</div><p>Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.</p>
<div class="lb-trans"><p>Vilobelimab 已在多个 II 期临床试验中进行评估，证明其在降低关键炎症标志物和改善临床结果方面的概念验证。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than InflaRx</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 InflaRx</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SUZSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IFRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in InflaRx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 InflaRx 吗？</h2>
</div><p>Before you consider InflaRx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 InflaRx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 InflaRx 并不在名单上。</p>
</div><p>While InflaRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 InflaRx 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

InflaRx (NASDAQ:IFRX) 公布了财报，每股收益超出预期 0.08 美元